Experts raise concerns over lower evidentiary standard for FDA’s leucovorin approval
Regulatory NewsJeff Craven
Approval/marketing authorizationPharmaceuticalsProduct LifecycleUnited StatesRegulatory NewsJeff CravenApproval/marketing authorizationPharmaceuticalsProduct LifecycleUnited States